US Health Officials Review Safety of RSV Shots Amid Anti-Vaccine Pressure
A move by US health officials under Secretary Robert F Kennedy Jr to re-examine the safety of RSV shots has raised concerns among experts. Despite no documented safety issues, the FDA's review could lead to restrictions on access to these life-saving vaccines.
RSV shots have been instrumental in reducing hospitalizations among infants in recent years. The vaccines are particularly effective when administered during pregnancy, with a 55-68% efficacy rate in preventing hospitalization in newborns. Babies who received the preventative antibody shots were 79-83% less likely to be hospitalized.
The decision by Kennedy's administration comes amidst pressure from anti-vaccine activists. Officials at the FDA told manufacturers of RSV treatments that their products are being reviewed due to safety concerns raised by these groups.
Dr. Elias Kass, a pediatrician specializing in naturopathy, praised the RSV shots as a groundbreaking tool for preventing complications. "The RSV shots were the first time we had any kind of tools to prevent these complications," he said. "To have a tool to prevent that is incredible."
However, experts worry that the review and potential restrictions on access could undermine public trust in vaccine safety. Kevin Ault, a former ACIP adviser and obstetrician/gynecologist, noted that there has been no new safety information released about RSV shots, despite concerns raised by anti-vaccine activists.
The move has also sparked concern among public health experts. "Decisions from the FDA could limit access to the shots, and without evidence, undermining the shots could affect public trust and confidence in vaccine safety," said Ault.
As the battle over vaccine safety continues, parents are already experiencing firsthand the devastating impact of RSV. The respiratory illness has been associated with developing asthma, and before widespread vaccination, 2% to 3% of all infants in the US were hospitalized for RSV.
A move by US health officials under Secretary Robert F Kennedy Jr to re-examine the safety of RSV shots has raised concerns among experts. Despite no documented safety issues, the FDA's review could lead to restrictions on access to these life-saving vaccines.
RSV shots have been instrumental in reducing hospitalizations among infants in recent years. The vaccines are particularly effective when administered during pregnancy, with a 55-68% efficacy rate in preventing hospitalization in newborns. Babies who received the preventative antibody shots were 79-83% less likely to be hospitalized.
The decision by Kennedy's administration comes amidst pressure from anti-vaccine activists. Officials at the FDA told manufacturers of RSV treatments that their products are being reviewed due to safety concerns raised by these groups.
Dr. Elias Kass, a pediatrician specializing in naturopathy, praised the RSV shots as a groundbreaking tool for preventing complications. "The RSV shots were the first time we had any kind of tools to prevent these complications," he said. "To have a tool to prevent that is incredible."
However, experts worry that the review and potential restrictions on access could undermine public trust in vaccine safety. Kevin Ault, a former ACIP adviser and obstetrician/gynecologist, noted that there has been no new safety information released about RSV shots, despite concerns raised by anti-vaccine activists.
The move has also sparked concern among public health experts. "Decisions from the FDA could limit access to the shots, and without evidence, undermining the shots could affect public trust and confidence in vaccine safety," said Ault.
As the battle over vaccine safety continues, parents are already experiencing firsthand the devastating impact of RSV. The respiratory illness has been associated with developing asthma, and before widespread vaccination, 2% to 3% of all infants in the US were hospitalized for RSV.